McKesson vs Sanofi

McKesson (MCK), health care, and Sanofi (SNY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

McKesson is worth $127B on the stock market and Sanofi $115B: McKesson is valued at 10% more. McKesson trades at 28.4 times earnings and Sanofi at 23.8; operating margins in their latest fiscal years were 1.54% and 14.5%. Over the past year McKesson's share price has moved +28.4% and Sanofi's -4.48%.

Key facts

McKesson market value
$127B
Sanofi market value
$115B
McKesson P/E
28.4
Sanofi P/E
23.8
McKesson revenue
$403.4BFY to 2026-03-31
Sanofi revenue
$48.4BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

McKesson vs Sanofi: every measure side by side
Measure McKesson Sanofi
SectorHealth CareHealth Care
Country United States France
Fiscal year ends2026-03-312025-12-31
Size
Market cap$127Bhigher$115Blower
Revenue$403.4Bhigher$48.4Blower
Earnings$4.8Blower$8.7Bhigher
Employees41,600lower74,846higher
Total assets$82.3Blower$140.7Bhigher
Valuation
P/E28.4higher23.8lower
P/S0.3lower2.4higher
P/B——
Dividend yield0.31%—
Profitability
Operating margin1.54%lower14.5%higher
Balance sheet
Net assets-$2.2Blower$79.2Bhigher
Total liabilities$83.2Bhigher$61.1Blower
Total debt$6.5Blower$20.8Bhigher
Cash on hand$4Blower$8.5Bhigher
Price change
Today-0.48%higher-1.05%lower
1 year+28.4%higher-4.48%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": McKesson / Sanofi). Who owns MCK · Who owns SNY

Further comparisons

Learn

Questions and answers

Which is bigger, McKesson or Sanofi?

By market value, McKesson is the larger: $127B against $115B for Sanofi. By revenue in its latest fiscal year, McKesson is the larger: $403.4B against $48.4B for Sanofi.

Which has the higher P/E ratio?

McKesson: 28.4, against 23.8 for Sanofi. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Sanofi: 14.5%, against 1.54% for McKesson. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Sanofi: $20.8B, against $6.5B for McKesson. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both McKesson and Sanofi?

In their latest 13F filings, Charles Brandes (founder) holds both.

Cite this page

Funkfolio, “McKesson vs Sanofi”, data as of 17 November 2026. https://funkfolio.com/compare/mck-vs-sny

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.